Floatz logo

Larotrectinib

Locally Advanced Malignant Solid Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

46 Active assets in the Locally Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 2BB
Pembrolizumab
Mayo Clinic
Phase 2BB
Epirubicin
Mayo Clinic
Phase 2BB
Carboplatin
Pamela Munster
Phase 2B
Alpelisib
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerDormant
BB
Indicative ·
65 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →